<?xml version="1.0"?>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article">
  <?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v3.0 20080202//EN?>
  <?DTDIdentifier.IdentifierType public?>
  <?SourceDTD.DTDName journalpublishing3.dtd?>
  <?SourceDTD.Version 3.0?>
  <?ConverterInfo.XSLTName jp2nlmx2.xsl?>
  <?ConverterInfo.Version 2?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Viszeralmedizin</journal-id>
      <journal-id journal-id-type="iso-abbrev">Viszeralmedizin</journal-id>
      <journal-id journal-id-type="publisher-id">VIM</journal-id>
      <journal-title-group>
        <journal-title>Viszeralmedizin</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1662-6664</issn>
      <issn pub-type="epub">1662-6672</issn>
      <publisher>
        <publisher-name>S. Karger Verlag f&#xFC;r Medizin und Naturwissenschaften GmbH</publisher-name>
        <publisher-loc>Wilhelmstrasse 20A, P.O. Box &#xB7; Postfach &#xB7; Case postale, D-79095, Freiburg, Germany &#xB7; Deutschland &#xB7; Allemagne, Phone: +49 761 45 20 70, Fax: +49 761 4 52 07 14, information@karger.de</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmcid">4513807</article-id>
      <article-id pub-id-type="doi">10.1159/000365099</article-id>
      <article-id pub-id-type="publisher-id">vim-0030-0156</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Review Article &#xB7; &#xDC;bersichtsarbeit</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Coeliac Disease &#x2013; New Pathophysiological Findings and Their Implications for Therapy</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Stein</surname>
            <given-names>J&#xFC;rgen</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">a</xref>
          <xref ref-type="aff" rid="aff2">b</xref>
          <xref ref-type="corresp" rid="cor1">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Schuppan</surname>
            <given-names>Detlef</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">c</xref>
          <xref ref-type="aff" rid="aff4">d</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><sup>a</sup>Department of Gastroenterology and Clinical Nutrition, Sachsenhausen Hospital, Teaching Hospital of the Goethe University Frankfurt, Germany</aff>
      <aff id="aff2"><sup>b</sup>Interdisciplinary Crohn Colitis Centre Rhein-Main, Frankfurt/M., Germany</aff>
      <aff id="aff3"><sup>c</sup>Institute of Translational Immunology, University Medical Center, Hospital Mainz, Germany</aff>
      <aff id="aff4"><sup>d</sup>Division of Gastroenterology, Beth Israel deaconess Medical Center, Harvard Medical School, Boston, MA, USA</aff>
      <author-notes>
        <corresp id="cor1">*Prof. Dr. med. Dr. oec. troph. J&#xFC;rgen Stein, Department of Gastroenterology and Clinical Nutrition, Krankenhaus Sachsenhausen, Teaching Hospital of the Goethe University Frankfurt, Schulstra&#xDF;e 31, 60594 Frankfurt, Germany, <email>J.Stein@em.uni-frankfurt.de</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>6</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>20</day>
        <month>6</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>1</day>
        <month>6</month>
        <year>2015</year>
      </pub-date>
      <!-- PMC Release delay is 12 months and 0 days and was based on the <pub-date pub-type="ppub"/>. -->
      <volume>30</volume>
      <issue>3</issue>
      <fpage>156</fpage>
      <lpage>165</lpage>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2014 by S. Karger GmbH, Freiburg</copyright-statement>
        <copyright-year>2014</copyright-year>
      </permissions>
      <abstract>
        <title>Summary</title>
        <p>Coeliac disease (CD) is one of the most common diseases worldwide, resulting from a combination of environmental (gluten) and genetic (human leucocyte antigen (HLA) and non-HLA genes) factors. Depending on the geographical location, the prevalence of CD has been estimated to approximate 0.5-1%. The only treatment currently available for CD is a gluten-free diet (GFD) excluding gluten-containing cereals such as wheat, rye, and barley, and other foodstuffs with natural or added gluten. However, adherence rates and patient acceptance are often poor. Moreover, even in fully adherent patients, the diet may fail to induce clinical or histological improvement. Hence, it is unsurprising that studies show CD patients to be highly interested in non-dietary alternatives. The following review focuses on current pathophysiological concepts of CD, spotlighting those pathways which may serve as new possible, non-dietary therapeutic targets in the treatment of CD.</p>
      </abstract>
      <trans-abstract xml:lang="de">
        <title>Zusammenfassung</title>
        <p>Die Z&#xF6;liakie ist weltweit eine der h&#xE4;ufigsten Erkrankungen, die aus einer Kombination von Umwelt-(Gluten) und genetischen (humanes Leukozyten-Antigen (HLA) und Nicht-HLA-Gene) Faktoren resultiert. Abh&#xE4;ngig von der geographischen Lage, wird die Pr&#xE4;valenz der Z&#xF6;liakie auf etwa 0,5-1% der Bev&#xF6;lkerung gesch&#xE4;tzt. Die einzige Behandlung, die derzeit bei Z&#xF6;liakie verf&#xFC;gbar ist, besteht in einer glutenfreien Di&#xE4;t (GFD), die glutenhaltige Getreide wie Weizen, Roggen und Gerste sowie andere Lebensmittel mit nat&#xFC;rlichem oder zugesetztem Gluten ausschlie&#xDF;t. Die Complianceraten und die Akzeptanz durch die Patienten sind jedoch oft schlecht. Weiterhin kann die Di&#xE4;t selbst bei Patienten, die diese vollst&#xE4;ndig einhalten, m&#xF6;glicherweise nicht zu einer klinischen oder histologischen Verbesserung f&#xFC;hren. Daher ist es nicht verwunderlich, dass Studien zeigen, dass Z&#xF6;liakie-Patienten sehr an nichtdi&#xE4;tetischen Alternativen interessiert sind. Die folgende &#xDC;bersicht konzentriert sich auf aktuelle pathophysiologische Konzepte der Z&#xF6;liakie, bei denen jene Signalwege herausgestellt werden, die als m&#xF6;gliche neue, nichtdi&#xE4;tetische therapeutische Ansatzpunkte in der Behandlung der Z&#xF6;liakie dienen k&#xF6;nnten.</p>
      </trans-abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>Coeliac disease</kwd>
        <kwd>Gluten-sensitive enteropathy</kwd>
        <kwd>Malabsorption</kwd>
        <kwd>Zonulin inhibitor</kwd>
        <kwd>Therapeutic vaccine</kwd>
        <kwd>Transglutaminase inhibitors</kwd>
      </kwd-group>
      <counts>
        <fig-count count="3"/>
        <table-count count="1"/>
        <ref-count count="95"/>
        <page-count count="10"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="sec1_1">
      <title>Introduction</title>
      <p>Coeliac disease (CD) is defined as chronic small intestinal immune-mediated enteropathy elicited by gluten and related prolamines in genetically predisposed individuals [<xref rid="B1" ref-type="bibr">1</xref>], and characterised by the presence of a variable combination of gluten-dependent clinical manifestations, CD-specific antibodies, HLA(human leucocyte antigen)-DQ2 or HLA-DQ8 haplotypes; a characteristic histomorphological picture of the proximal small intestinal mucosa (inflammatory infiltrate, crypt hyperplasia, villous atrophy); and remission of clinical and serologic findings on keeping a gluten-free diet (GFD).</p>
      <p>CD occurs in genetically susceptible populations in many regions worldwide, with a prevalence of 0.5-1% in Americans and Europeans, as well as in the populations of Australia, North Africa, the Middle East, India, and probably also northern China (depending on the prevalence of HLA-DQ2 and HLA-DQ8). In some populations, including those of Finland and Mexico, and among the Sahrawi children of North Africa, the prevalence lies between 2 and 5% [<xref rid="B2" ref-type="bibr">2</xref>].</p>
      <p>CD can manifest itself clinically at any age. The disease aetiology is multifactorial, with a strong genetic susceptibility, as documented in studies of twins and in studies demonstrating a strong dependence on HLA-DQ2 and HLA-DQ8 haplotypes [<xref rid="B3" ref-type="bibr">3</xref>].</p>
      <p>The clinical manifestations of CD can vary considerably, from none at all (asymptomatic CD) to a wide spectrum of intestinal symptoms such as diarrhoea, steatorrhoea and malabsorption (classical CD), and atypical symptoms (e.g. neurologic findings including depression and gluten ataxia; reproductive disease, including abnormalities in menarche and menopause; and oral/cutaneous disease, including dermatitis herpetiformis). Refractory CD (RCD), based on the expression of a clonal TCR-&#x3B3; chain gene by intraepithelial lymphocytes (IELs) and divided into two types, RCD I and RCD II, is characterised by persistent or recurrent malabsorptive symptoms and signs with villous atrophy (VA) despite adherence to a strict GFD for more than 12 months (for review see [<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B6" ref-type="bibr">6</xref>]). While RCD I is associated with a slight increase of mortality, RCD II is a far more serious form of the disease, with a 5-year mortality rate of up to 50% following diagnosis. Patients with RCD II have also been shown to be at the highest risk of enteropathy-associated T cell lymphoma (EATL) [<xref rid="B7" ref-type="bibr">7</xref>,<xref rid="B8" ref-type="bibr">8</xref>].</p>
      <p>Although it is now some 60 years since Willem Dicke [<xref rid="B9" ref-type="bibr">9</xref>], a Dutch paediatrician, demonstrated a &#x2018;wheat factor&#x2019; as the causative agent of CD, a lifelong GFD remains to this day the only effective treatment [<xref rid="B10" ref-type="bibr">10</xref>]. While daily gluten consumption in the general population has been calculated to be approximately 15-20 g [<xref rid="B11" ref-type="bibr">11</xref>], several studies have demonstrated that daily doses of as little as &lt;1 g are sufficient to induce mucosal lesions in CD patients. For CD patients, 10-50 mg gluten per day has been shown to be a safe threshold [<xref rid="B12" ref-type="bibr">12</xref>,<xref rid="B13" ref-type="bibr">13</xref>,<xref rid="B14" ref-type="bibr">14</xref>].</p>
      <p>Although more than 95% of patients with CD have an uncomplicated disease that resolves under a GFD, the adherence rates and patient acceptance vary [<xref rid="B15" ref-type="bibr">15</xref>,<xref rid="B16" ref-type="bibr">16</xref>]. Furthermore, even in fully adherent patients, the diet fails to induce clinical or histological improvement in 7-30% of the patients [<xref rid="B17" ref-type="bibr">17</xref>,<xref rid="B18" ref-type="bibr">18</xref>,<xref rid="B19" ref-type="bibr">19</xref>], and 2-5% of the patients develop RCD [<xref rid="B20" ref-type="bibr">20</xref>,<xref rid="B21" ref-type="bibr">21</xref>].</p>
      <p>Furthermore, while quality of life (QOL) has been shown to improve after diagnosis and subsequent to GFD introduction, some studies found reduced health-related QOL [<xref rid="B22" ref-type="bibr">22</xref>,<xref rid="B23" ref-type="bibr">23</xref>]. CD patients on a GFD may also develop nutritional deficiencies [<xref rid="B24" ref-type="bibr">24</xref>,<xref rid="B25" ref-type="bibr">25</xref>].</p>
      <p>Unsurprisingly, a recent study demonstrated that a large proportion of patients with CD is dissatisfied with the GFD and therefore seeks therapeutic alternatives to it [<xref rid="B26" ref-type="bibr">26</xref>].</p>
      <p>Based on an improved understanding of the pathogenic pathways underlying CD, several types of therapeutic approach with the potential to augment or supplant the GFD have been generated. This article aims to review novel non-dietary approaches based on new pathophysiological findings and their implications for therapy.</p>
    </sec>
    <sec id="sec1_2">
      <title>Pathogenesis of Coeliac Disease</title>
      <p>The pathogenesis of CD is multifaceted, involving environmental (gluten, intestinal infections), genetic, and immunological factors (fig. <xref ref-type="fig" rid="F1">1</xref>).</p>
      <sec id="sec2_1">
        <title>Environmental Factors &#x2013; the Role of Dietary Proteins</title>
        <p>Proteins in the dietary cereal grains wheat, rye, and barley &#x2013; collectively termed &#x2018;gluten&#x2019; &#x2013; are known to be the environmental factors which cause disease exacerbation. Strictly speaking, however, gluten is the scientific name only for wheat proteins, while the related proteins in barley and rye capable of activating CD are known as hordeins and secalins, respectively. Whereas wheat, rye, and barley have a common ancestral origin in the grass family, oats, which only rarely (if at all) trigger CD, are more distantly related, thus lacking many of the proteins found in wheat. In contrast, the proteins found in rice, maize, sorghum, and millet, which are even more distantly related, do not activate CD.</p>
        <p>Gluten contains more than a hundred proteins, present either as monomers or as oligomers and polymers, and linked by interchain disulphide bonds characterised by high content of glutamine and proline (in the form of prolamines), and by low content of charged amino acids. Based on the availability of complete amino acid sequences, gluten can be divided into three broad groups: sulphur-rich (S-rich), sulphur-poor (S-poor), and high-molecular-weight (HMW) prolamines. Traditionally, gluten proteins have been classified according to their solubility in alcohol-water solutions (e.g. 60% ethanol) as soluble gliadins and insoluble glutenins. The alcohol-soluble gliadin fraction consists mainly of monomeric proteins, which either lack cysteine (&#x3C9;-gliadins) or have only intrachain disulphide bonds (&#x3B1;-type and &#x3B3;-type gliadins). &#x3C9;-gliadins are characterised by the highest content of glutamine, proline, and phenylalanine, accounting for around 80% of the total composition [<xref rid="B27" ref-type="bibr">27</xref>].</p>
        <p>The exceptionally high glutamine and proline content in the gliadins and glutenins of wheat, and also in hordeins and secalins, plays a key role in the pathogenesis of CD:</p>
        <p>i) Lacking sufficient prolyl endopeptidases in the human intestine, the high proline content renders these proteins relatively resistant to proteolytic digestion, resulting in the accumulation of relatively large toxic peptides (mainly 50 amino acids in length);</p>
        <p>ii) Due to their high content of glutamine and hydrophobic amino acid residues, gluten proteins, especially the alcohol-soluble fraction (e.g. gliadins of wheat, secalins of barley, and hordeins of rye) but also the glutenins, are preferred substrates for the ubiquitous cellular enzyme tissue transglutaminase 2 (tTG2). TG2 can either crosslink certain glutamines in one protein chain with a lysine residue on another chain by forming a covalent isopeptide bond, or merely deamidate this glutamine to an acidic glutamic acid residue, which is of major importance for the pathogenesis of CD.</p>
        <p>More than 50 distinct (deamidated) gluten peptides exerting cytotoxic, immunomodulatory, and gut-permeating activities have been described [<xref rid="B28" ref-type="bibr">28</xref>]. These activities have been partially mapped to specific domains in &#x3B1;-gliadin (fig. <xref ref-type="fig" rid="F2">2</xref>): the cytotoxic peptides 31-43 and 31-49, the immunomodulatory peptide 57-89 (33-mer), the CXCR3-binding, zonulin-releasing (gut-permeating) peptides 111-130 and 151-170, and the interleukin(IL)-8-releasing peptide 261-277. The 33mer peptide from &#x3B1;2-gliadin, which contains 6 partly overlapping HLA-DQ2-binding amino acid sequences and is also regarded as a coeliac &#x2018;superantigen&#x2019; [<xref rid="B28" ref-type="bibr">28</xref>,<xref rid="B29" ref-type="bibr">29</xref>], has been shown to be resistant to degradation by gastrointestinal peptidases reaching the submucosal immune system in an intact peptide [<xref rid="B30" ref-type="bibr">30</xref>].</p>
        <p>After reaching the lamina propria, either by epithelial trans cytosis or through increased epithelial tight junctional permeability, gluten peptides are deamidated through the activity of tTG2, and (except the 33mer peptide, which does not need further processing) [<xref rid="B31" ref-type="bibr">31</xref>,<xref rid="B32" ref-type="bibr">32</xref>] presented in the lamina propria by dendritic cells to activate CD4<sup>+</sup> T cells [<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B33" ref-type="bibr">33</xref>].</p>
        <p>In contrast, the cytotoxic &#x3B1;-gliadin peptides p31-49 and p31-49, which are thought not to bind to HLA-DQ2 and -DQ8, have been shown to upregulate IL-15 production in epithelial cells, macrophages, and dendritic cells, thus increasing IEL infiltration and epithelial cell apoptosis via NKGD2D und MICA receptors, respectively cumulating in cytotoxic damage to the epithelium [<xref rid="B29" ref-type="bibr">29</xref>,<xref rid="B33" ref-type="bibr">33</xref>,<xref rid="B34" ref-type="bibr">34</xref>].</p>
      </sec>
      <sec id="sec2_2">
        <title>Genetic Factors</title>
        <p>Evidence for genetically-based susceptibility for CD has been gained from epidemiological studies showing that up to 20% of first-degree kin are equally affected by CD, with concordance rates &gt;75% in monozygotic twins [<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B35" ref-type="bibr">35</xref>]. The leucocyte antigen (HLA) class II genes HLA-DQ2 and -DQ8 have been demonstrated to be the strongest genetic susceptibility factors by far: Whereas more than 95% of CD patients carry HLA-DQ2 and -DQ8, these genes are found in only 25-30% of the Caucasian population, of whom only 4% develop CD, indicating that additional factors also play a role. Using genome-wide association study (GWAS), at least 115 genes harbouring non-HLA susceptibility factors associated with CD have been described, of which 28 have been shown to be immune-related [<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B36" ref-type="bibr">36</xref>]. However, these genes do not contribute more than 4-5% to the overall genetic risk, which is dominated by HLA-DQ2 or -DQ8.</p>
      </sec>
      <sec id="sec2_3">
        <title>Immunological Factors</title>
        <p>HLA-DQ2 and -DQ8 play a plausible key role in CD due to their unique ability to bind the proline-rich gluten peptides, especially those with a negative charge due to TG2-mediated deamidation, resulting in a more rigorous CD+ Th1 T cell activation. Both HLA-DQ2 and -DQ8, such as the lysine positioned at &#x3B2;71 and at positions P4, P6, and P7 of DQ2, contain positively-charged pockets which promote the binding of negatively-charged glutamic acid residues generated by the autoantigen TG2 (fig. <xref ref-type="fig" rid="F3">3</xref>) [<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B29" ref-type="bibr">29</xref>].</p>
        <p>Gluten-responsive activated T cells produce proinflammatory cytokines, predominantly interferon-&#x3B3; (IFN-&#x3B3;). IFN-&#x3B3; activates macrophages, which in turn secrete tumour necrosis factor &#x3B1; (TNF-&#x3B1;) and proteolytic matrix metalloproteinases (MMPs). Both cytokines trigger the expression of proteolytic MMPs in intestinal myofibroblasts, resulting in matrix proteolysis alteration, which in turn leads to mucosal injury and villous atrophy. In addition, via a phosphatidylinositol-3-kinase-dependent pathway and mediated by thioredoxin (TRX), IFN-&#x3B3; triggers the activation of tTG2, thereby establishing an autoamplificatory loop for gluten-induced inflammation [<xref rid="B37" ref-type="bibr">37</xref>]. In duodenal biopsies of CD patients, neutralisation of IFN-&#x3B3; has been shown to ameliorate gluten-induced mucosal damage [<xref rid="B38" ref-type="bibr">38</xref>].</p>
        <p>Chronic exposure of CD patients to dietary gluten is invariably accompanied by the production of autoantibodies against tTG2. Anti-tTG2 antibodies are preferentially localised in the subepithelial layer, where they adhere to extracellular tTG2 on fibroblasts and on the basement membrane of the small intestine. Anti-tTG2 have been shown to induce enterocyte proliferation and inhibit enterocyte differentiation, and are able to modulate epithelial barrier function, thereby promoting intestinal crypt hyperplasia and villous blunting (reviewed in [<xref rid="B37" ref-type="bibr">37</xref>]).</p>
      </sec>
    </sec>
    <sec id="sec1_3">
      <title>Non-Dietary Therapies of Coeliac Disease</title>
      <p>As already mentioned, a lifelong GFD is not only burdensome, but difficult to maintain and frequently unsuccessful. Thus, there is a need for effective, inexpensive, and safe alternative treatment options for CD and new approaches in adjunctive therapy. Although, at the present time, it is unrealistic for such novel therapies to counteract effects of gluten at the levels typically contained in the Western diet (15-20 g daily), their initial aim should be to neutralise at least small amounts of up to 3 g gluten per day. Since few therapeutic alternatives are currently available to treat RCD, more costly compounds with less favourable side-effect profiles may be acceptable in these patients. In the second part of this paper, we discuss new treatment strategies for the future which have shown potential in early studies in CD, with encouraging results in vivo and in vitro.</p>
      <p>Novel non-dietary treatment options can be classified by their targets during different phases in the pathogenesis of CD (e.g. candidates targeting the disease-inducing prolamines, endogenous molecules involved in the pathogenesis) or by their ability to induce tolerance to gluten (fig. <xref ref-type="fig" rid="F2">2</xref>).</p>
    </sec>
    <sec id="sec1_4">
      <title>Targeting Disease-Inducing Gluten and Other Prolamines</title>
      <sec id="sec2_4">
        <title>Preventing Intestinal Gluten (Prolamine) Absorption</title>
        <p>Another strategy to prevent the interaction of immunogenic gluten peptides with submucosal immune cells is the use of HMW polymers to selectively bind gluten, thereby preventing its breakdown and absorption [<xref rid="B39" ref-type="bibr">39</xref>].</p>
        <p>Poly(hydroxyethylmethacrylate-co-styrene sulfonate (P(HEMA-co-SS))) is a synthetic polymeric compound that sequesters food-derived gluten in the gastrointestinal lumen by forming high-affinity complexes with &#x3B1;-gliadin, thus preventing enzymatic digestion of gluten and other prolamines into smaller, medium-length immunogenic peptides [<xref rid="B39" ref-type="bibr">39</xref>,<xref rid="B40" ref-type="bibr">40</xref>].</p>
        <p>In a first preclinical study, Pinier et al. [<xref rid="B41" ref-type="bibr">41</xref>] assessed the capacity of P(HEMA-co-SS), a copolymer of hydroxyethyl methacrylate and styrene sulfonate, to reduce paracellular permeability, and demonstrated its ability to normalise antigliadin immunoglobulin A in intestinal washes and reduce gliadin-invoked TNF-&#x3B1; secretion in duodenal biopsies of CD patients.</p>
      </sec>
    </sec>
    <sec id="sec1_5">
      <title>Oral Enzyme Therapy</title>
      <p>Because the human digestive tract has an insufficient supply of prolyl endopeptidases (PEPs), the enzymes capable of hydrolysing the immunogenic proline-rich peptides found in gluten and related prolamines, oral PEP therapy may offer another strategy to reduce the amounts of immunogenic gluten peptides reaching the small intestine. This approach is analogous to exogenous lactase supplementation in the treatment of lactose intolerance. Enzymatically active PEPs are expressed in several microbial species, including <italic>Aspergillus niger, Sphingomonas capsulata, Flavobacterium meningosepticum</italic>, and <italic>Myxococcus</italic>[<xref rid="B42" ref-type="bibr">42</xref>].</p>
      <p><italic>A. niger</italic> PEP (AN-PEP) is enzymatically active in a pH ranging from 2 to 8, and is therefore active both in the stomach and in the intestine. It has also been shown to be resistant to gastric pepsin. In vitro, AN-PEP is able to break down gluten and gluten peptides into non-immunogenic fragments within a few minutes [<xref rid="B43" ref-type="bibr">43</xref>,<xref rid="B44" ref-type="bibr">44</xref>]. A recent pilot study of 16 subjects demonstrated AN-PEP to be well-tolerated, but no efficacy data have been presented [<xref rid="B45" ref-type="bibr">45</xref>].</p>
      <p>PEPs derived from <italic>F. meningosepticum</italic> (PEP-FM) have been shown to effectively reduce levels of the immunogenic 33mer in vitro and in vivo in rats. However, subsequent studies revealed that large quantities of the enzyme would be required to detoxify a normal daily gluten intake, and that PEP-FM activity decreased due to its instability in the presence of gastric enzymes [<xref rid="B42" ref-type="bibr">42</xref>,<xref rid="B46" ref-type="bibr">46</xref>].</p>
      <p>To enhance gluten degradation, combinations of complementary peptides have been introduced [<xref rid="B47" ref-type="bibr">47</xref>]. ALV003 is composed of two gluten-specific proteases: a modified recombinant version of a <italic>Hordeum vulgare</italic> (barley) cysteine endoprotease (EP-B2) and a modified recombinant version of a <italic>S</italic>.<italic>capsulata</italic> prolyl endopeptidase.</p>
      <p>In a phase IIb trial involving 41 patients with stable CD, in which individuals were randomised to receive oral ALV003 or placebo daily for 6 weeks at the time of ingestion of 2 g gluten, ALV003 was reported to significantly attenuate gluten-induced intestinal mucosal injury. Importantly, no serious adverse events were reported.</p>
      <p>Currently, a growing number of enzyme preparations claiming to aid gluten digestion are becoming commercially available, e.g. compounds containing dipeptidyl peptidase IV (DPPIV) from <italic>Aspergillus oryzae</italic>[<xref rid="B48" ref-type="bibr">48</xref>]. However, their effectiveness in CD patients has not been confirmed in clinical trials.</p>
    </sec>
    <sec id="sec1_6">
      <title>Decreasing Intestinal Permeability</title>
      <p>Increased intestinal permeability (IP) in active CD has been measured both clinically by non-invasive sugar permeability tests (e.g. urinary lactose/mannitol (LAMA) fractional excretion ratio) [<xref rid="B49" ref-type="bibr">49</xref>] and by in vitro tight junction (TJ) analysis [<xref rid="B50" ref-type="bibr">50</xref>]. Although it is not yet finally determined whether increased IP is a primary cause or a consequence of CD, an increase of IP via opening epithelial TJs seems to be an important contributor to the influx of gluten peptides into the subepithelial adaptive immune system.</p>
      <p>The <italic>Vibrio cholera</italic> zona occludens toxin (ZOT) is known to increase intestinal paracellular permeability by altering different TJ proteins via the 66 kD ZOT receptor (for review see [<xref rid="B28" ref-type="bibr">28</xref>]). Based on the observation that the inflamed intestinal epithelium of CD patients releases a paracrine protein (zonulin) [<xref rid="B51" ref-type="bibr">51</xref>], which acts similar to ZOT, an octapeptide (AT-1001) corresponding to the amino acid sequence of the receptor-binding motif of human zonulin was developed. By antagonising zonulin receptor activation, AT-1001 thus protects intestinal TJ integrity.</p>
      <p>Based on encouraging data from a phase I trial showing that AT-1001 (larazotide acetate) was not only well tolerated, but also decreased IP, IFN-&#x3B3; production, and intestinal symptoms following a single gluten challenge in CD patients, phase II placebo-controlled randomised trials were performed. In the study of Leffler et al. [<xref rid="B52" ref-type="bibr">52</xref>], 86 patients with CD in diet-controlled remission were randomly assigned to larazotide acetate (0.25, 1, 4, or 8 mg) or placebo three times per day with or without gluten challenge (2.4 g/day) for 14 days. Although the primary efficacy endpoint (decrease of LAMA fractional excretion ratio) was not reached, larazotide acetate improved gluten-induced exacerbation of gastrointestinal symptom severity as measured by the Gastrointestinal Symptom Rating Scale (GSRS) at lower doses, but not at the higher dose [<xref rid="B52" ref-type="bibr">52</xref>]. No serious adverse events were observed. In a dose-escalation study (1.4 and 8 mg) in 184 CD patients in remission who were challenged with 0.9 g gluten three times daily over 42 days, Kelly et al. [<xref rid="B53" ref-type="bibr">53</xref>] demonstrated that, compared to placebo controls, patients treated with larazotide acetate showed a significantly improved symptom score and a less pronounced anti-tTG response. However, this study also failed to demonstrate significant improvement in IP as measured by the urinary LAMA ratio.</p>
      <p>Results from the first multicentre trial conducted in 74 sites in North America, including 342 patients, were presented as a late breaker abstract at the 2014 Digestive Disease Week (DDW) in Chicago, reporting significant symptom reduction under the 0.5 mg dose of larazotide acetate. This study represents the largest therapeutic trial in CD to meet its primary endpoint of reducing signs and symptoms [<xref rid="B54" ref-type="bibr">54</xref>].</p>
    </sec>
    <sec id="sec1_7">
      <title>Preventing T Cell Activation by Gluten-Derived Peptides</title>
      <sec id="sec2_5">
        <title>Blocking Deamidation of Gluten-Derived Peptides: Transglutaminase Inhibitors</title>
        <p>Although the deamidation of gluten by tTG may not be an absolute prerequisite for the initiation of CD, it does at least play an important role, increasing T cell reactivity by improving peptide affinity to HLA-DQ2 and -DQ8 molecules. Therefore, therapeutic approaches targeting the inhibition of tTG would seem logical.</p>
        <p>Several competitive (mainly polyamines, e.g. putrescine, spermidine, or cystamine), reversible (mainly guanosine triphosphate analogues), and irreversible (e.g. iodoacetamide, 3-halo-4.5-dihydroisoxazoles) inhibitors have been developed [<xref rid="B55" ref-type="bibr">55</xref>,<xref rid="B56" ref-type="bibr">56</xref>,<xref rid="B57" ref-type="bibr">57</xref>,<xref rid="B58" ref-type="bibr">58</xref>,<xref rid="B59" ref-type="bibr">59</xref>,<xref rid="B60" ref-type="bibr">60</xref>], which have been demonstrated in vitro to be able to attenuate the toxic effects of gliadin in epithelial cell cultures. A few have also been tested successfully ex vivo in duodenal biopsy specimens of CD patients. More recently, a group of high-affinity tTG2 inhibitors (ZED 1098, ZED 1219, and Zedira) has been developed, shown to be stable and soluble in the GI tract and not cytotoxic over a wide dosing range [<xref rid="B47" ref-type="bibr">47</xref>].</p>
      </sec>
      <sec id="sec2_6">
        <title>Blocking the Binding of Deamidated Gluten Peptides to HLA Proteins: HLA-DQ2 Inhibitors</title>
        <p>Alternatively, blocking the binding of deamidated gluten peptides to CD-specific HLA proteins from interacting with antigen-presenting cells could also be a promising approach. A similar strategy has already been tested in other autoimmune diseases (e.g. type 1 diabetes, rheumatoid arthritis) but results in terms of clinical efficacy have been disappointing, presumably due to inadequate drug delivery. In spite of new technological advancements (e.g. use of a positional scanning nonapeptide library or silico approach) [<xref rid="B61" ref-type="bibr">61</xref>,<xref rid="B62" ref-type="bibr">62</xref>,<xref rid="B63" ref-type="bibr">63</xref>,<xref rid="B64" ref-type="bibr">64</xref>] allowing the development of ultra-high affinity peptides, in light of specific requirements regarding nontoxicity and non-immunogenicity, this approach still requires a great deal of work before reaching clinical practice.</p>
      </sec>
    </sec>
    <sec id="sec1_8">
      <title>Therapy Targeted at Immune Cells</title>
      <sec id="sec2_7">
        <title>Immunosuppression by Topical Steroids</title>
        <p>Budesonide, a topical glucocorticoid with low systemic bioavailability mainly used in inflammatory bowel disease (IBD) affecting the distal part of the intestine, was reported to be effective also in the treatment both of RCD (e.g. non-responsive to GFD) [<xref rid="B65" ref-type="bibr">65</xref>,<xref rid="B66" ref-type="bibr">66</xref>] and non-RCD [<xref rid="B67" ref-type="bibr">67</xref>]. Presumably, changing the drug formulation to target the proximal intestine should further improve its efficacy for CD.</p>
      </sec>
      <sec id="sec2_8">
        <title>Inhibitors of T Cell Homing</title>
        <p>As in other T cell-mediated disease (e.g. IBD), homing of effector/memory T cells to the small intestine (i.e. the intestinal segment affected by CD) is mainly controlled by their expression of the cell surface chemokine receptor CCR9 and the integrin &#x3B1;4&#x3B2;7. Antibodies targeting CCR9 and &#x3B1;4&#x3B2;7 to prevent or limit T cell migration (homing) to the small intestine, thereby limiting local T cell activation, may also reduce intestinal damage and are therefore a potentially promising therapy for (refractory) CD.</p>
        <p>Vedolizumab, a humanised anti-&#x3B1;4&#x3B2;7 integrin antibody, has been approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) in 2014 as the first anti-adhesion therapy for the treatment of IBD. Phase II trials have shown that etrolizumab, a humanised monoclonal IgG1 antibody targeting &#x3B2;7, is effective for the treatment of ulcerative colitis (reviewed in [<xref rid="B68" ref-type="bibr">68</xref>]). Currently, there are no data from CD trials.</p>
        <p>Encouraging results for CCX282-B, a specific, orally-administered chemokine receptor CCR9 antagonist, in a clinical phase II trial in patients with Crohn's disease, have already led to the initiation of phase III clinical trials in CD [<xref rid="B69" ref-type="bibr">69</xref>]. Also, a phase II clinical study in CD (ClinicalTrials.gov identifier: NCT00540657) has already been completed, although publishing of the results is still pending.</p>
      </sec>
      <sec id="sec2_9">
        <title>Inhibitors of Proinflammatory Cytokines</title>
        <p>The central role of IL-15 in the onset and the severity of CD is evidenced by both animal and human data [<xref rid="B70" ref-type="bibr">70</xref>,<xref rid="B71" ref-type="bibr">71</xref>,<xref rid="B72" ref-type="bibr">72</xref>,<xref rid="B73" ref-type="bibr">73</xref>,<xref rid="B74" ref-type="bibr">74</xref>]. Based on the potent immune-modulating effects of IL-15, blockage of the IL-15 pathway either via the inhibition of IL-15 or by blocking the IL-15 receptor, or inhibition of the downstream JAK3-kinase, may be especially useful approaches for the treatment of RCD. In a phase I/II clinical trial in rheumatoid arthritis (RA), HuMax-IL15, a human monoclonal antibody targeting IL-15 (HuMax-IL15; Genmab, Copenhagen, Denmark) which blocks the epitope of IL-15 binding to the c subunit of the IL-15 receptor, was well tolerated and effected substantial improvements in disease activity [<xref rid="B74" ref-type="bibr">74</xref>].</p>
        <p>Tofacitinib, an oral inhibitor of the Janus kinases 1.2 and 3 which blocks signalling involving gamma chain-containing cytokines such as IL-15, has recently been demonstrated in phase II trials to be highly effective in the treatment of RA [<xref rid="B75" ref-type="bibr">75</xref>] and IBD [<xref rid="B76" ref-type="bibr">76</xref>,<xref rid="B77" ref-type="bibr">77</xref>]. These studies suggest that manipulation of the IL-15 pathway might also have therapeutic possibilities in CD, especially for RCD and EATL, in which malignant T cell expansion is driven by IL-15. Although there are as yet no data from clinical studies in CD, recently published results from animal studies [<xref rid="B78" ref-type="bibr">78</xref>] would encourage further research of this strategy.</p>
      </sec>
      <sec id="sec2_10">
        <title>Targeting IFN-&#x3B3; and TNF-&#x3B1;</title>
        <p>IFN-&#x3B3;, produced by submucosal gliadin-sensitive CD4<sup>+</sup> T cells, triggers the activation of MMPs and is thus responsible for mucosal injury and villous atrophy. In addition, by increasing intestinal permeability, probably via a Rho-associated kinase-dependent pathway, it promotes the influx of gliadin peptides through the intestinal wall [<xref rid="B79" ref-type="bibr">79</xref>,<xref rid="B80" ref-type="bibr">80</xref>,<xref rid="B81" ref-type="bibr">81</xref>]. A small study using biopsies from the intestinal mucosa of patients with CD demonstrated that IFN-&#x3B3;-blocking antibodies were able to prevent mucosal damage induced by pro-inflammatory cytokines released by gliadin-specific HLA-DQ2-restricted T lymphocyte clones [<xref rid="B82" ref-type="bibr">82</xref>]. However, at least in Crohn's disease, phase II clinical trials using IFN-&#x3B3; monoclonal antibodies have not shown very promising results [<xref rid="B83" ref-type="bibr">83</xref>,<xref rid="B84" ref-type="bibr">84</xref>].</p>
        <p>A more promising approach seems to be to target TNF-&#x3B1;, which has been found to be more elevated in RCD [<xref rid="B85" ref-type="bibr">85</xref>]. The use of monoclonal antibodies against TNF-&#x3B1;, which has now been the mainstay in the treatment of Crohn's disease for more than 10 years, has been described in several case reports in the treatment of RCD [<xref rid="B86" ref-type="bibr">86</xref>,<xref rid="B87" ref-type="bibr">87</xref>,<xref rid="B88" ref-type="bibr">88</xref>,<xref rid="B89" ref-type="bibr">89</xref>,<xref rid="B90" ref-type="bibr">90</xref>].</p>
      </sec>
      <sec id="sec2_11">
        <title>CXCR3/CXCL10 Inhibitors</title>
        <p>CXCL10, also referred to as IFN-&#x3B3;-inducible protein-10 (IP-10), is another chemokine which plays an important role in the integrin activation and migration of activated T cells, monocytes, and natural killer cells. Stimulation of IP-10 by the chemokine receptor 3 (CXCR3) results in the generation and recruitment of proinflammatory cells responsible for inflammation and tissue destruction [<xref rid="B91" ref-type="bibr">91</xref>]. Recently, Lammers et al. [<xref rid="B92" ref-type="bibr">92</xref>] identified a novel immunomodulatory gliadin peptide that causes IL-8 release in a chemokine receptor CXCR3-dependent manner exclusively in patients with CD, supporting the CXCR3/CXCL10 axis as a future therapeutic target for CD.</p>
        <p>In a most recently published phase II trial by Sandborn et al. [<xref rid="B76" ref-type="bibr">76</xref>], BMS-936557, a human monoclonal antibody targeting CXCL10, was well tolerated and produced substantial improvements in disease activity in patients with moderately-to-severely active ulcerative colitis. To this day, clinical data from CD patients are lacking.</p>
      </sec>
    </sec>
    <sec id="sec1_9">
      <title>Immune Modulation and Induction of Tolerance to Gluten Peptides</title>
      <p>A phase Ib/IIa trial of infection with the nematode <italic>Necator americanus</italic> in patients with CD, aiming to effect a shift from a Th1 to a Th2 milieu, has recently been reported. However, despite promising safety data, the study failed to show obvious improvement in disease activity following gluten challenge [<xref rid="B93" ref-type="bibr">93</xref>].</p>
      <p>Also currently under investigation is NexVax2, a therapeutic vaccine derived from a mixture of three 15- to 16mer peptides aiming to generate gluten tolerance. A phase I study of NexVax2 in 40 HLA-DQ2+ CD patients, using subcutaneous doses of up to 90 &#xB5;g vaccine weekly for 3 weeks, showed no clinically relevant adverse events [<xref rid="B94" ref-type="bibr">94</xref>]. Based on these promising safety data, further trials to examine long-term efficacy are warranted.</p>
    </sec>
    <sec sec-type="conclusions" id="sec1_10">
      <title>Conclusion</title>
      <p>Recent progress made in understanding the pathogenesis of CD has opened the doors for a variety of new non-dietary treatments which may be used at least as adjunctive therapy (table <xref ref-type="table" rid="T1">1</xref>). To date, however, only a limited number of experimental therapies for CD have been assessed in phase I-II randomised, controlled clinical trials. Larazotide acetate (AT-1001), which is assumed to hinder the paracellular passage of gluten through the epithelial barrier into the lamina propria by inhibiting tight junctions, has been studied in almost 100 patients to date, but an effect on hard end points, such as protection of mucosal integrity, needs to be demonstrated. Though fewer patients were studied, evidence for the efficacy of the endopeptidases contained in ALV003 which break down gluten to less or non-immunogenic peptide fragments is more obvious. Other therapies like TG2 inhibition, preventing immunogenic potentiation of gluten, or vaccination to induce tolerance to ingested gluten are less advanced but have potential for high efficacy. It should be kept in mind that most therapies discussed do not have the potential to allow the ingestion of gluten at normal daily levels of &gt;15 g, but offer only an adjunctive therapy, eliminating the detrimental effects of small amounts of up to a few grams of gluten in CD patients. However, in light of the relative ease at which the obvious sources of gluten can be avoided in contrast to the many nutritional sources of hidden gluten, even a &#x2018;neutralization&#x2019; of a minor amount of gluten would take most of the dietary burden from patients with CD.</p>
    </sec>
    <sec id="sec1_11">
      <title>Disclosure Statement</title>
      <p>JS: No conflict of interest to declare. DS: Royalties from Eurospital, Trieste, Italy.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ludvigsson</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Leffler</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Bai</surname>
              <given-names>JC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The Oslo definitions for coeliac disease and related terms</article-title>
          <source>Gut</source>
          <year>2013</year>
          <volume>62</volume>
          <fpage>43</fpage>
          <lpage>52</lpage>
          <pub-id pub-id-type="pmid">22345659</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schuppan</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Zimmer</surname>
              <given-names>KP</given-names>
            </name>
          </person-group>
          <article-title>The diagnosis and treatment of celiac disease</article-title>
          <source>Dtsch Arztebl Int</source>
          <year>2013</year>
          <volume>110</volume>
          <fpage>835</fpage>
          <lpage>846</lpage>
          <pub-id pub-id-type="pmid">24355936</pub-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abadie</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Sollid</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Barreiro</surname>
              <given-names>LB</given-names>
            </name>
            <name>
              <surname>Jabri</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Integration of genetic and immunological insights into a model of celiac disease pathogenesis</article-title>
          <source>Annu Rev Immunol</source>
          <year>2011</year>
          <volume>29</volume>
          <fpage>493</fpage>
          <lpage>525</lpage>
          <pub-id pub-id-type="pmid">21219178</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Green</surname>
              <given-names>PH</given-names>
            </name>
          </person-group>
          <article-title>The many faces of celiac disease: clinical presentation of celiac disease in the adult population</article-title>
          <source>Gastroenterology</source>
          <year>2005</year>
          <volume>128</volume>
          <fpage>S74</fpage>
          <lpage>78</lpage>
          <pub-id pub-id-type="pmid">15825130</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Green</surname>
              <given-names>PH</given-names>
            </name>
            <name>
              <surname>Jabri</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Coeliac disease</article-title>
          <source>Lancet</source>
          <year>2003</year>
          <volume>362</volume>
          <fpage>383</fpage>
          <lpage>391</lpage>
          <pub-id pub-id-type="pmid">12907013</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Green</surname>
              <given-names>PH</given-names>
            </name>
            <name>
              <surname>Cellier</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Celiac disease</article-title>
          <source>N Engl J Med</source>
          <year>2007</year>
          <volume>12</volume>
          <issue>357</issue>
          <fpage>1731</fpage>
          <lpage>1743</lpage>
          <pub-id pub-id-type="pmid">17960014</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Malamut</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Afchain</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Verkarre</surname>
              <given-names>V</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type II</article-title>
          <source>Gastroenterology</source>
          <year>2009</year>
          <volume>136</volume>
          <fpage>81</fpage>
          <lpage>90</lpage>
          <pub-id pub-id-type="pmid">19014942</pub-id>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Malamut</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Cellier</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Refractory celiac disease</article-title>
          <source>Gastrointest Endosc Clin N Am</source>
          <year>2012</year>
          <volume>22</volume>
          <fpage>759</fpage>
          <lpage>772</lpage>
          <pub-id pub-id-type="pmid">23083992</pub-id>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dicke</surname>
              <given-names>WK</given-names>
            </name>
            <name>
              <surname>Weijers</surname>
              <given-names>HA</given-names>
            </name>
            <name>
              <surname>Van De Kamer</surname>
              <given-names>JH</given-names>
            </name>
          </person-group>
          <article-title>Coeliac disease</article-title>
          <source>II. The presence in wheat of a factor having a deleterious effect in cases of coeliac disease. Acta Paediatr</source>
          <year>1953</year>
          <volume>42</volume>
          <fpage>34</fpage>
          <lpage>42</lpage>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fasano</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Catassi</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Clinical practice</article-title>
          <source>Celiac disease. N Engl J Med</source>
          <year>2012</year>
          <volume>367</volume>
          <fpage>2419</fpage>
          <lpage>2426</lpage>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>van Overbeek</surname>
              <given-names>FM</given-names>
            </name>
            <name>
              <surname>Uil-Dieterman</surname>
              <given-names>IG</given-names>
            </name>
            <name>
              <surname>Mol</surname>
              <given-names>IW</given-names>
            </name>
            <name>
              <surname>K&#xF6;hler-Brands</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Heymans</surname>
              <given-names>HS</given-names>
            </name>
            <name>
              <surname>Mulder</surname>
              <given-names>CJ</given-names>
            </name>
          </person-group>
          <article-title>The daily gluten intake in relatives of patients with coeliac disease compared with that of the general Dutch population</article-title>
          <source>Eur J Gastroenterol Hepatol</source>
          <year>1997</year>
          <volume>9</volume>
          <fpage>1097</fpage>
          <lpage>1099</lpage>
          <pub-id pub-id-type="pmid">9431901</pub-id>
        </element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Collin</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Thorell</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Kaukinen</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Maki</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>The safe threshold for gluten contamination in gluten-free products</article-title>
          <source>Can trace amounts be accepted in the treatment of coeliac disease? Aliment Pharmacol Ther</source>
          <year>2004</year>
          <volume>19</volume>
          <fpage>1277</fpage>
          <lpage>1283</lpage>
        </element-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Catassi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Fabiani</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Iacono</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease</article-title>
          <source>Am J Clin Nutr</source>
          <year>2007</year>
          <volume>85</volume>
          <fpage>160</fpage>
          <lpage>166</lpage>
          <pub-id pub-id-type="pmid">17209192</pub-id>
        </element-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hischenhuber</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Crevel</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Jarry</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Review article: safe amounts of gluten for patients with wheat allergy or coeliac disease</article-title>
          <source>Aliment Pharmacol Ther</source>
          <year>2006</year>
          <volume>23</volume>
          <fpage>559</fpage>
          <lpage>575</lpage>
          <pub-id pub-id-type="pmid">16480395</pub-id>
        </element-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hall</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Rubin</surname>
              <given-names>GP</given-names>
            </name>
            <name>
              <surname>Charnock</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Intentional and inadvertent non-adherence in adult coeliac disease</article-title>
          <source>A cross-sectional survey. Appetite</source>
          <year>2013</year>
          <volume>68</volume>
          <fpage>56</fpage>
          <lpage>62</lpage>
        </element-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hall</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Rubin</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Charnock</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Systematic review: adherence to a gluten-free diet in adult patients with coeliac disease</article-title>
          <source>Aliment Pharmacol Ther</source>
          <year>2009</year>
          <volume>30</volume>
          <fpage>315</fpage>
          <lpage>330</lpage>
          <pub-id pub-id-type="pmid">19485977</pub-id>
        </element-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Midhagen</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Hallert</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>High rate of gastrointestinal symptoms in celiac patients living on a gluten-free diet: controlled study</article-title>
          <source>Am J Gastroenterol</source>
          <year>2003</year>
          <volume>98</volume>
          <fpage>2023</fpage>
          <lpage>2026</lpage>
          <pub-id pub-id-type="pmid">14499782</pub-id>
        </element-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bardella</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Velio</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Cesana</surname>
              <given-names>BM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Coeliac disease: a histological follow-up study</article-title>
          <source>Histopathology</source>
          <year>2007</year>
          <volume>50</volume>
          <fpage>465</fpage>
          <lpage>471</lpage>
          <pub-id pub-id-type="pmid">17448022</pub-id>
        </element-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tuire</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Marja-Leena</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Teea</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Persistent duodenal intraepithelial lymphocytosis despite a long-term strict gluten-free diet in celiac disease</article-title>
          <source>Am J Gastroenterol</source>
          <year>2012</year>
          <volume>107</volume>
          <fpage>1563</fpage>
          <lpage>1569</lpage>
          <pub-id pub-id-type="pmid">22825364</pub-id>
        </element-citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Daum</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Cellier</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Mulder</surname>
              <given-names>CJ</given-names>
            </name>
          </person-group>
          <article-title>Refractory coeliac disease</article-title>
          <source>Best Pract Res Clin Gastroenterol</source>
          <year>2005</year>
          <volume>19</volume>
          <fpage>413</fpage>
          <lpage>424</lpage>
          <pub-id pub-id-type="pmid">15925846</pub-id>
        </element-citation>
      </ref>
      <ref id="B21">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rubio-Tapia</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>Classification and management of refractory coeliac disease</article-title>
          <source>Gut</source>
          <year>2010</year>
          <volume>59</volume>
          <fpage>547</fpage>
          <lpage>557</lpage>
          <pub-id pub-id-type="pmid">20332526</pub-id>
        </element-citation>
      </ref>
      <ref id="B22">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hauser</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Stallmach</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Caspary</surname>
              <given-names>WF</given-names>
            </name>
            <name>
              <surname>Stein</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Predictors of reduced health-related quality of life in adults with coeliac disease</article-title>
          <source>Aliment Pharmacol Ther</source>
          <year>2007</year>
          <volume>25</volume>
          <fpage>569</fpage>
          <lpage>578</lpage>
          <pub-id pub-id-type="pmid">17305757</pub-id>
        </element-citation>
      </ref>
      <ref id="B23">
        <label>23</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hauser</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Gold</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Stein</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Caspary</surname>
              <given-names>WF</given-names>
            </name>
            <name>
              <surname>Stallmach</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Health-related quality of life in adult coeliac disease in Germany: results of a national survey</article-title>
          <source>Eur J Gastroenterol Hepatol</source>
          <year>2006</year>
          <volume>18</volume>
          <fpage>747</fpage>
          <lpage>754</lpage>
          <pub-id pub-id-type="pmid">16772832</pub-id>
        </element-citation>
      </ref>
      <ref id="B24">
        <label>24</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hallert</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Grant</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Grehn</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Evidence of poor vitamin status in coeliac patients on a gluten-free diet for 10 years</article-title>
          <source>Aliment Pharmacol Ther</source>
          <year>2002</year>
          <volume>16</volume>
          <fpage>1333</fpage>
          <lpage>1339</lpage>
          <pub-id pub-id-type="pmid">12144584</pub-id>
        </element-citation>
      </ref>
      <ref id="B25">
        <label>25</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Martin</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Geisel</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Maresch</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Krieger</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Stein</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Inadequate nutrient intake in patients with celiac disease: results from a German dietary survey</article-title>
          <source>Digestion</source>
          <year>2013</year>
          <volume>87</volume>
          <fpage>240</fpage>
          <lpage>246</lpage>
          <pub-id pub-id-type="pmid">23751356</pub-id>
        </element-citation>
      </ref>
      <ref id="B26">
        <label>26</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aziz</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Evans</surname>
              <given-names>KE</given-names>
            </name>
            <name>
              <surname>Papageorgiou</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Sanders</surname>
              <given-names>DS</given-names>
            </name>
          </person-group>
          <article-title>Are patients with coeliac disease seeking alternative therapies to a gluten-free diet?</article-title>
          <source>J Gastrointestin Liver Dis</source>
          <year>2011</year>
          <volume>20</volume>
          <fpage>27</fpage>
          <lpage>31</lpage>
          <pub-id pub-id-type="pmid">21451794</pub-id>
        </element-citation>
      </ref>
      <ref id="B27">
        <label>27</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wieser</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Chemistry of gluten proteins</article-title>
          <source>Food Microbiol</source>
          <year>2007</year>
          <volume>24</volume>
          <fpage>115</fpage>
          <lpage>119</lpage>
          <pub-id pub-id-type="pmid">17008153</pub-id>
        </element-citation>
      </ref>
      <ref id="B28">
        <label>28</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fasano</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer</article-title>
          <source>Physiol Rev</source>
          <year>2011</year>
          <volume>91</volume>
          <fpage>151</fpage>
          <lpage>175</lpage>
          <pub-id pub-id-type="pmid">21248165</pub-id>
        </element-citation>
      </ref>
      <ref id="B29">
        <label>29</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schuppan</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Junker</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Barisani</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Celiac disease: from pathogenesis to novel therapies</article-title>
          <source>Gastroenterology</source>
          <year>2009</year>
          <volume>137</volume>
          <fpage>1912</fpage>
          <lpage>1933</lpage>
          <pub-id pub-id-type="pmid">19766641</pub-id>
        </element-citation>
      </ref>
      <ref id="B30">
        <label>30</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shan</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Molberg &#xD8;Parrot</surname>
              <given-names>I</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Structural basis for gluten intolerance in celiac sprue</article-title>
          <source>Science</source>
          <year>2002</year>
          <volume>297</volume>
          <fpage>2275</fpage>
          <lpage>2279</lpage>
          <pub-id pub-id-type="pmid">12351792</pub-id>
        </element-citation>
      </ref>
      <ref id="B31">
        <label>31</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Qiao</surname>
              <given-names>SW1</given-names>
            </name>
            <name>
              <surname>Bergseng</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Molberg</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Jung</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Fleckenstein</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Sollid</surname>
              <given-names>LM</given-names>
            </name>
          </person-group>
          <article-title>Refining the rules of gliadin T cell epitope binding to the disease-associated DQ2 molecule in celiac disease: importance of proline spacing and glutamine deamidation</article-title>
          <source>J Immunol</source>
          <year>2005</year>
          <volume>175</volume>
          <fpage>254</fpage>
          <lpage>261</lpage>
          <pub-id pub-id-type="pmid">15972656</pub-id>
        </element-citation>
      </ref>
      <ref id="B32">
        <label>32</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Qiao</surname>
              <given-names>SW</given-names>
            </name>
            <name>
              <surname>Bergseng</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Molberg</surname>
              <given-names>&#xD8;</given-names>
            </name>
            <name>
              <surname>Xia</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Fleckenstein</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Khosla</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Sollid</surname>
              <given-names>LM</given-names>
            </name>
          </person-group>
          <article-title>Antigen presentation to celiac lesion-derived T cells of a 33-mer gliadin peptide naturally formed by gastrointestinal digestion</article-title>
          <source>J Immunol</source>
          <year>2004</year>
          <volume>173</volume>
          <fpage>1757</fpage>
          <lpage>1762</lpage>
          <pub-id pub-id-type="pmid">15265905</pub-id>
        </element-citation>
      </ref>
      <ref id="B33">
        <label>33</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kagnoff</surname>
              <given-names>MF</given-names>
            </name>
          </person-group>
          <article-title>Celiac disease: pathogenesis of a model immunogenetic disease</article-title>
          <source>J Clin Invest</source>
          <year>2007</year>
          <volume>117</volume>
          <fpage>41</fpage>
          <lpage>49</lpage>
          <pub-id pub-id-type="pmid">17200705</pub-id>
        </element-citation>
      </ref>
      <ref id="B34">
        <label>34</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>De Re</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Caggiari</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Tabuso</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cannizzaro</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>The versatile role of gliadin peptides in celiac disease</article-title>
          <source>Clin Biochem</source>
          <year>2013</year>
          <volume>46</volume>
          <fpage>552</fpage>
          <lpage>560</lpage>
          <pub-id pub-id-type="pmid">23142684</pub-id>
        </element-citation>
      </ref>
      <ref id="B35">
        <label>35</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kupfer</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Jabri</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Pathophysiology of celiac disease</article-title>
          <source>Gastrointest Endosc Clin N A</source>
          <year>2012</year>
          <volume>22</volume>
          <fpage>639</fpage>
          <lpage>660</lpage>
        </element-citation>
      </ref>
      <ref id="B36">
        <label>36</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Trynka</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Wijmenga</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>van Heel</surname>
              <given-names>DA</given-names>
            </name>
          </person-group>
          <article-title>A genetic perspective on coeliac disease</article-title>
          <source>Trends Mol Med</source>
          <year>2010</year>
          <volume>16</volume>
          <fpage>537</fpage>
          <lpage>550</lpage>
          <pub-id pub-id-type="pmid">20947431</pub-id>
        </element-citation>
      </ref>
      <ref id="B37">
        <label>37</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Klock</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Diraimondo</surname>
              <given-names>TR</given-names>
            </name>
            <name>
              <surname>Khosla</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Role of transglutaminase 2 in celiac disease pathogenesis</article-title>
          <source>Semin Immunopathol</source>
          <year>2012</year>
          <volume>34</volume>
          <fpage>513</fpage>
          <lpage>522</lpage>
          <pub-id pub-id-type="pmid">22437759</pub-id>
        </element-citation>
      </ref>
      <ref id="B38">
        <label>38</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Diraimondo</surname>
              <given-names>TR</given-names>
            </name>
            <name>
              <surname>Klock</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Khosla</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Interferon-gamma activates transglutaminase 2 via a phosphatidylinositol-3-kinase-dependent pathway: implications for celiac sprue therapy</article-title>
          <source>J Pharmacol Exp Ther</source>
          <year>2012</year>
          <volume>341</volume>
          <fpage>104</fpage>
          <lpage>114</lpage>
          <pub-id pub-id-type="pmid">22228808</pub-id>
        </element-citation>
      </ref>
      <ref id="B39">
        <label>39</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Pinier</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Leroux</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Subirade</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Interaction of alpha-gliadin with polyanions: design considerations for sequestrants used in supportive treatment of celiac disease</article-title>
          <source>Biopolymers</source>
          <year>2010</year>
          <volume>93</volume>
          <fpage>418</fpage>
          <lpage>428</lpage>
          <pub-id pub-id-type="pmid">19921745</pub-id>
        </element-citation>
      </ref>
      <ref id="B40">
        <label>40</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Pinier</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Leroux</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Subirade</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Interaction of alpha-gliadin with poly(HEMA-co-SS): structural characterization and biological implication</article-title>
          <source>Biopolymers</source>
          <year>2009</year>
          <volume>91</volume>
          <fpage>169</fpage>
          <lpage>178</lpage>
          <pub-id pub-id-type="pmid">18975377</pub-id>
        </element-citation>
      </ref>
      <ref id="B41">
        <label>41</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pinier</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fuhrmann</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Galipeau</surname>
              <given-names>HJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The copolymer P(HEMA-co-SS) binds gluten and reduces immune response in gluten-sensitized mice and human tissues</article-title>
          <source>Gastroenterology</source>
          <year>2012</year>
          <volume>142</volume>
          <fpage>316</fpage>
          <lpage>325</lpage>
          <comment>e1-12</comment>
          <pub-id pub-id-type="pmid">22079593</pub-id>
        </element-citation>
      </ref>
      <ref id="B42">
        <label>42</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gass</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Khosla</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Prolyl endopeptidases</article-title>
          <source>Cell Mol Life Sci</source>
          <year>2007</year>
          <volume>64</volume>
          <fpage>345</fpage>
          <lpage>355</lpage>
          <pub-id pub-id-type="pmid">17160352</pub-id>
        </element-citation>
      </ref>
      <ref id="B43">
        <label>43</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stepniak</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Spaenij-Dekking</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Mitea</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Highly efficient gluten degradation with a newly identified prolyl endoprotease: implications for celiac disease</article-title>
          <source>Am J Physiol Gastrointest Liver Physiol</source>
          <year>2006</year>
          <volume>291</volume>
          <fpage>G621</fpage>
          <lpage>629</lpage>
          <pub-id pub-id-type="pmid">16690904</pub-id>
        </element-citation>
      </ref>
      <ref id="B44">
        <label>44</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Edens</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Dekker</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>van der Hoeven</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Extracellular prolyl endoprotease from <italic>Aspergillus niger</italic> and its use in the debittering of protein hydrolysates</article-title>
          <source>J Agric Food Chem</source>
          <year>2005</year>
          <volume>53</volume>
          <fpage>7950</fpage>
          <lpage>7957</lpage>
          <pub-id pub-id-type="pmid">16190655</pub-id>
        </element-citation>
      </ref>
      <ref id="B45">
        <label>45</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tack</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>van de Water</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Bruins</surname>
              <given-names>MJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Consumption of gluten with gluten-degrading enzyme by celiac patients: a pilot-study</article-title>
          <source>World J Gastroenterol</source>
          <year>2013</year>
          <volume>19</volume>
          <fpage>5837</fpage>
          <lpage>5847</lpage>
          <pub-id pub-id-type="pmid">24124328</pub-id>
        </element-citation>
      </ref>
      <ref id="B46">
        <label>46</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shan</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Marti</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Sollid</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Gray</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Khosla</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Comparative biochemical analysis of three bacterial prolyl endopeptidases: implications for coeliac sprue</article-title>
          <source>Biochem J</source>
          <year>2004</year>
          <volume>383</volume>
          <fpage>311</fpage>
          <lpage>318</lpage>
          <pub-id pub-id-type="pmid">15245330</pub-id>
        </element-citation>
      </ref>
      <ref id="B47">
        <label>47</label>
        <element-citation publication-type="other">
          <person-group person-group-type="author">
            <name>
              <surname>Kurppa</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hietikko</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sulic</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Kaukinen</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Lindfors</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Current status of drugs in development for celiac disease</article-title>
          <source>Expert Opin Investig Drugs</source>
          <year>2014</year>
          <comment>DOI: 10.1517/13543784.2014.916274.</comment>
        </element-citation>
      </ref>
      <ref id="B48">
        <label>48</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ehren</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Mor&#xF3;n</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Bethune</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Gray</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Khosla</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>A food-grade enzyme preparation with modest gluten detoxification properties</article-title>
          <source>PloS One</source>
          <year>2009</year>
          <volume>4</volume>
          <fpage>e6313</fpage>
          <pub-id pub-id-type="pmid">19621078</pub-id>
        </element-citation>
      </ref>
      <ref id="B49">
        <label>49</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>van Elburg</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Uil</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Mulder</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Heymans</surname>
              <given-names>HS</given-names>
            </name>
          </person-group>
          <article-title>Intestinal permeability in patients with coeliac disease and relatives of patients with coeliac disease</article-title>
          <source>Gut</source>
          <year>1993</year>
          <volume>34</volume>
          <fpage>354</fpage>
          <lpage>357</lpage>
          <pub-id pub-id-type="pmid">8472983</pub-id>
        </element-citation>
      </ref>
      <ref id="B50">
        <label>50</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schulzke</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Bentzel</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Schulzke</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Riecken,</surname>
              <given-names>EO</given-names>
            </name>
            <name>
              <surname>Fromm</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Epithelial tight junction structure in the jejunum of children with acute and treated celiac sprue</article-title>
          <source>Pediatr Res</source>
          <year>1998</year>
          <volume>43</volume>
          <fpage>435</fpage>
          <lpage>441</lpage>
          <pub-id pub-id-type="pmid">9544995</pub-id>
        </element-citation>
      </ref>
      <ref id="B51">
        <label>51</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Drago</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>El Asmar</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Di Pierro</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Gliadin, zonulin and gut permeability: effects on celiac and non-celiac intestinal mucosa and intestinal cell lines</article-title>
          <source>Scand J Gastroenterol</source>
          <year>2006</year>
          <volume>41</volume>
          <fpage>408</fpage>
          <lpage>419</lpage>
          <pub-id pub-id-type="pmid">16635908</pub-id>
        </element-citation>
      </ref>
      <ref id="B52">
        <label>52</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Leffler</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Kelly</surname>
              <given-names>CP</given-names>
            </name>
            <name>
              <surname>Abdallah</surname>
              <given-names>HZ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge</article-title>
          <source>Am J Gastroenterol</source>
          <year>2012</year>
          <volume>107</volume>
          <fpage>1554</fpage>
          <lpage>1562</lpage>
          <pub-id pub-id-type="pmid">22825365</pub-id>
        </element-citation>
      </ref>
      <ref id="B53">
        <label>53</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kelly</surname>
              <given-names>CP</given-names>
            </name>
            <name>
              <surname>Green</surname>
              <given-names>PH</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>JA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study</article-title>
          <source>Aliment Pharmacol Ther</source>
          <year>2013</year>
          <volume>37</volume>
          <fpage>252</fpage>
          <lpage>262</lpage>
          <pub-id pub-id-type="pmid">23163616</pub-id>
        </element-citation>
      </ref>
      <ref id="B54">
        <label>54</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Rasmussen</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Perrow</surname>
              <given-names>W</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Larazotide acetate, a first in-class, novel tight junction regulator, meets primary endpoint and significantly reduces signs and symptoms of celiac disease in patients on a gluten-free diet: results of a multicenter, randomized, placebo controlled trial</article-title>
          <source>Gastroenterology</source>
          <year>2014</year>
          <volume>146</volume>
          <fpage>S</fpage>
          <lpage>15</lpage>
        </element-citation>
      </ref>
      <ref id="B55">
        <label>55</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kapoerchan</surname>
              <given-names>VV</given-names>
            </name>
            <name>
              <surname>Wiesner</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Overhand</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Design of azidoproline containing gluten peptides to suppress CD4(+) T-cell responses associated with celiac disease</article-title>
          <source>Bioorg Med Chem</source>
          <year>2008</year>
          <volume>16</volume>
          <fpage>2053</fpage>
          <lpage>2062</lpage>
          <pub-id pub-id-type="pmid">18037302</pub-id>
        </element-citation>
      </ref>
      <ref id="B56">
        <label>56</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Badarau</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Mongeot</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Collighan</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Rathbone</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Griffin</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Imidazolium-based warheads strongly influence activity of water-soluble peptidic transglutaminase inhibitors</article-title>
          <source>Eur J Med Chem</source>
          <year>2013</year>
          <volume>66</volume>
          <fpage>526</fpage>
          <lpage>530</lpage>
          <pub-id pub-id-type="pmid">23835447</pub-id>
        </element-citation>
      </ref>
      <ref id="B57">
        <label>57</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Badarau</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Collighan</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Griffin</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Recent advances in the development of tissue transglutaminase (TG2) inhibitors</article-title>
          <source>Amino Acids</source>
          <year>2013</year>
          <volume>44</volume>
          <fpage>119</fpage>
          <lpage>127</lpage>
          <pub-id pub-id-type="pmid">22160259</pub-id>
        </element-citation>
      </ref>
      <ref id="B58">
        <label>58</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ozaki</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ebisui</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Hamada</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Potent transglutaminase inhibitors, dithio beta-aminoethyl ketones</article-title>
          <source>Bioorg Med Chem Lett</source>
          <year>2011</year>
          <volume>21</volume>
          <fpage>377</fpage>
          <lpage>379</lpage>
          <pub-id pub-id-type="pmid">21134746</pub-id>
        </element-citation>
      </ref>
      <ref id="B59">
        <label>59</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ozaki</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ebisui</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Hamada</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Potent transglutaminase inhibitors, aryl beta-aminoethyl ketones</article-title>
          <source>Bioorg Med Chem Lett</source>
          <year>2010</year>
          <volume>20</volume>
          <fpage>1141</fpage>
          <lpage>1144</lpage>
          <pub-id pub-id-type="pmid">20053561</pub-id>
        </element-citation>
      </ref>
      <ref id="B60">
        <label>60</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Watts</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Siegel</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Khosla</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Structure-activity relationship analysis of the selective inhibition of transglutaminase 2 by dihydroisoxazoles</article-title>
          <source>J Med Chem</source>
          <year>2006</year>
          <volume>49</volume>
          <fpage>7493</fpage>
          <lpage>7501</lpage>
          <pub-id pub-id-type="pmid">17149878</pub-id>
        </element-citation>
      </ref>
      <ref id="B61">
        <label>61</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Juse</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Arntzen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hojrup</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Fleckenstein</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Sollid</surname>
              <given-names>LM</given-names>
            </name>
          </person-group>
          <article-title>Assessing high affinity binding to HLA-DQ2.5 by a novel peptide library based approach</article-title>
          <source>Bioorg Med Chemistry</source>
          <year>2011</year>
          <volume>19</volume>
          <fpage>2470</fpage>
          <lpage>2477</lpage>
        </element-citation>
      </ref>
      <ref id="B62">
        <label>62</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stepniak</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Wiesner</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>de Ru</surname>
              <given-names>AH</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Large-scale characterization of natural ligands explains the unique gluten-binding properties of HLA-DQ2</article-title>
          <source>J Immunol</source>
          <year>2008</year>
          <volume>180</volume>
          <fpage>3268</fpage>
          <lpage>3278</lpage>
          <pub-id pub-id-type="pmid">18292551</pub-id>
        </element-citation>
      </ref>
      <ref id="B63">
        <label>63</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kapoerchan</surname>
              <given-names>VV</given-names>
            </name>
            <name>
              <surname>Wiesner</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hillaert</surname>
              <given-names>U</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Design, synthesis and evaluation of high-affinity binders for the celiac disease associated HLA-DQ2 molecule</article-title>
          <source>Mol Immunol</source>
          <year>2010</year>
          <volume>47</volume>
          <fpage>1091</fpage>
          <lpage>1097</lpage>
          <pub-id pub-id-type="pmid">19962195</pub-id>
        </element-citation>
      </ref>
      <ref id="B64">
        <label>64</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Juse</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>van de Wal</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Koning</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Sollid</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Fleckenstein</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Design of new high-affinity peptide ligands for human leukocyte antigen-DQ2 using a positional scanning peptide library</article-title>
          <source>Hum Immunol</source>
          <year>2010</year>
          <volume>71</volume>
          <fpage>475</fpage>
          <lpage>481</lpage>
          <pub-id pub-id-type="pmid">20105447</pub-id>
        </element-citation>
      </ref>
      <ref id="B65">
        <label>65</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Daum</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ipczynski</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Heine</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Therapy with budesonide in patients with refractory sprue</article-title>
          <source>Digestion</source>
          <year>2006</year>
          <volume>73</volume>
          <fpage>60</fpage>
          <lpage>68</lpage>
          <pub-id pub-id-type="pmid">16612091</pub-id>
        </element-citation>
      </ref>
      <ref id="B66">
        <label>66</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brar</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lewis</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Budesonide in the treatment of refractory celiac disease</article-title>
          <source>Am J Gastroenterol</source>
          <year>2007</year>
          <volume>102</volume>
          <fpage>2265</fpage>
          <lpage>2269</lpage>
          <pub-id pub-id-type="pmid">17581265</pub-id>
        </element-citation>
      </ref>
      <ref id="B67">
        <label>67</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ciacci</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Maiuri</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Russo</surname>
              <given-names>I</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Efficacy of budesonide therapy in the early phase of treatment of adult coeliac disease patients with malabsorption: an in vivo/in vitro pilot study</article-title>
          <source>Clin Exp Pharmacol Physiol</source>
          <year>2009</year>
          <volume>36</volume>
          <fpage>1170</fpage>
          <lpage>1176</lpage>
          <pub-id pub-id-type="pmid">19473192</pub-id>
        </element-citation>
      </ref>
      <ref id="B68">
        <label>68</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lobaton</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Vermeire</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Van Assche</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Rutgeerts</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Review article: anti-adhesion therapies for inflammatory bowel disease</article-title>
          <source>Aliment Pharmacol Ther</source>
          <year>2014</year>
          <volume>39</volume>
          <fpage>579</fpage>
          <lpage>594</lpage>
          <pub-id pub-id-type="pmid">24479980</pub-id>
        </element-citation>
      </ref>
      <ref id="B69">
        <label>69</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Keshav</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Va&#xC0;&#xE1;sek</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Niv</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease</article-title>
          <source>PloS One</source>
          <year>2013</year>
          <volume>8</volume>
          <fpage>e60094</fpage>
          <pub-id pub-id-type="pmid">23527300</pub-id>
        </element-citation>
      </ref>
      <ref id="B70">
        <label>70</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Malamut</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>El Machhour</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Montcuquet</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease-associated inflammation and lymphomagenesis</article-title>
          <source>J Clin Invest</source>
          <year>2010</year>
          <volume>120</volume>
          <fpage>2131</fpage>
          <lpage>2143</lpage>
          <pub-id pub-id-type="pmid">20440074</pub-id>
        </element-citation>
      </ref>
      <ref id="B71">
        <label>71</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yokoyama</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Watanabe</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Sato</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Anti-body-mediated blockade of IL-15 reverses the autoimmune intestinal damage in transgenic mice that overexpress IL-15 in enterocytes</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>2009</year>
          <volume>106</volume>
          <fpage>15849</fpage>
          <lpage>15854</lpage>
          <pub-id pub-id-type="pmid">19805228</pub-id>
        </element-citation>
      </ref>
      <ref id="B72">
        <label>72</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mention</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Ben Ahmed</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>B&#xE8;gue</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Interleukin 15: a key to disrupted intraepithelial lymphocyte homeostasis and lymphomagenesis in celiac disease</article-title>
          <source>Gastroenterology</source>
          <year>2003</year>
          <volume>125</volume>
          <fpage>730</fpage>
          <lpage>745</lpage>
          <pub-id pub-id-type="pmid">12949719</pub-id>
        </element-citation>
      </ref>
      <ref id="B73">
        <label>73</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maiuri</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Ciacci</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Auricchio</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Interleukin 15 mediates epithelial changes in celiac disease</article-title>
          <source>Gastroenterology</source>
          <year>2000</year>
          <volume>119</volume>
          <fpage>996</fpage>
          <lpage>1006</lpage>
          <pub-id pub-id-type="pmid">11040186</pub-id>
        </element-citation>
      </ref>
      <ref id="B74">
        <label>74</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Baslund</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Tvede</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Danneskiold-Samsoe</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study</article-title>
          <source>Arthritis Rheum</source>
          <year>2005</year>
          <volume>52</volume>
          <fpage>2686</fpage>
          <lpage>2692</lpage>
          <pub-id pub-id-type="pmid">16142748</pub-id>
        </element-citation>
      </ref>
      <ref id="B75">
        <label>75</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Van Vollenhoven</surname>
              <given-names>RF1</given-names>
            </name>
            <name>
              <surname>Fleischmann</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Tofacitinib or adalimumab versus placebo in rheumatoid arthritis</article-title>
          <source>N Engl J Med</source>
          <year>2012</year>
          <volume>367</volume>
          <fpage>508</fpage>
          <lpage>519</lpage>
          <pub-id pub-id-type="pmid">22873531</pub-id>
        </element-citation>
      </ref>
      <ref id="B76">
        <label>76</label>
        <element-citation publication-type="other">
          <person-group person-group-type="author">
            <name>
              <surname>Sandborn</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Ghosh</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Panes</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A phase 2 study of tofacitinib, an oral janus kinase inhibitor, in patients with Crohn's disease</article-title>
          <source>Clin Gastroenterol Hepatol</source>
          <year>2014</year>
          <comment>DOI: 10.1016/j.cgh.2014.01.029.</comment>
        </element-citation>
      </ref>
      <ref id="B77">
        <label>77</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sandborn</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Ghosh</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Panes</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis</article-title>
          <source>N Engl J Med</source>
          <year>2012</year>
          <volume>367</volume>
          <fpage>616</fpage>
          <lpage>624</lpage>
          <pub-id pub-id-type="pmid">22894574</pub-id>
        </element-citation>
      </ref>
      <ref id="B78">
        <label>78</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yokoyama</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Perera</surname>
              <given-names>PY</given-names>
            </name>
            <name>
              <surname>Waldmann</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Hiroi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Perera</surname>
              <given-names>LP</given-names>
            </name>
          </person-group>
          <article-title>Tofacitinib, a janus kinase inhibitor demonstrates efficacy in an IL-15 transgenic mouse model that recapitulates pathologic manifestations of celiac disease</article-title>
          <source>J Clin Immunol</source>
          <year>2013</year>
          <volume>33</volume>
          <fpage>586</fpage>
          <lpage>594</lpage>
          <pub-id pub-id-type="pmid">23269601</pub-id>
        </element-citation>
      </ref>
      <ref id="B79">
        <label>79</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Utech</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ivanov</surname>
              <given-names>AI</given-names>
            </name>
            <name>
              <surname>Samarin</surname>
              <given-names>SN</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mechanism of IFN-gamma-induced endocytosis of tight junction proteins: myosin II-dependent vacuolarization of the apical plasma membrane</article-title>
          <source>Mol Biol Cell</source>
          <year>2005</year>
          <volume>16</volume>
          <fpage>5040</fpage>
          <lpage>5052</lpage>
          <pub-id pub-id-type="pmid">16055505</pub-id>
        </element-citation>
      </ref>
      <ref id="B80">
        <label>80</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Beaurepaire</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Smyth</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>McKay</surname>
              <given-names>DM</given-names>
            </name>
          </person-group>
          <article-title>Interferon-gamma regulation of intestinal epithelial permeability</article-title>
          <source>J Interferon Cytokine Res</source>
          <year>2009</year>
          <volume>29</volume>
          <fpage>133</fpage>
          <lpage>144</lpage>
          <pub-id pub-id-type="pmid">19196071</pub-id>
        </element-citation>
      </ref>
      <ref id="B81">
        <label>81</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bethune</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Siegel</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Howles-Banerji</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Khosla</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Interferon-gamma released by gluten-stimulated celiac disease-specific intestinal T cells enhances the transepithelial flux of gluten peptides</article-title>
          <source>J Pharmacol Exp Ther</source>
          <year>2009</year>
          <volume>329</volume>
          <fpage>657</fpage>
          <lpage>668</lpage>
          <pub-id pub-id-type="pmid">19218531</pub-id>
        </element-citation>
      </ref>
      <ref id="B82">
        <label>82</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Przemioslo</surname>
              <given-names>RT</given-names>
            </name>
            <name>
              <surname>Lundin</surname>
              <given-names>KE</given-names>
            </name>
            <name>
              <surname>Sollid</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Nelufer</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ciclitira</surname>
              <given-names>PJ</given-names>
            </name>
          </person-group>
          <article-title>Histological changes in small bowel mucosa induced by gliadin sensitive T lymphocytes can be blocked by anti-interferon gamma antibody</article-title>
          <source>Gut</source>
          <year>1995</year>
          <volume>36</volume>
          <fpage>874</fpage>
          <lpage>879</lpage>
          <pub-id pub-id-type="pmid">7615276</pub-id>
        </element-citation>
      </ref>
      <ref id="B83">
        <label>83</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reinisch</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>de Villiers</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Bene</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study</article-title>
          <source>Inflamm Bowel Dis</source>
          <year>2010</year>
          <volume>16</volume>
          <fpage>233</fpage>
          <lpage>242</lpage>
          <pub-id pub-id-type="pmid">19637334</pub-id>
        </element-citation>
      </ref>
      <ref id="B84">
        <label>84</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hommes</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Mikhajlova</surname>
              <given-names>TL</given-names>
            </name>
            <name>
              <surname>Stoinov</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease</article-title>
          <source>Gut</source>
          <year>2006</year>
          <volume>55</volume>
          <fpage>1131</fpage>
          <lpage>1137</lpage>
          <pub-id pub-id-type="pmid">16507585</pub-id>
        </element-citation>
      </ref>
      <ref id="B85">
        <label>85</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Caruso</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Marafini</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Sedda</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Analysis of the cytokine profile in the duodenal mucosa of refractory coeliac disease patients</article-title>
          <source>Clin Sci</source>
          <year>2014</year>
          <volume>126</volume>
          <fpage>451</fpage>
          <lpage>458</lpage>
          <pub-id pub-id-type="pmid">24125165</pub-id>
        </element-citation>
      </ref>
      <ref id="B86">
        <label>86</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Valitutti</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Barbato</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Aloi</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Autoimmune enteropathy in a 13-year-old celiac girl successfully treated with infliximab</article-title>
          <source>J Clin Gastroenterol</source>
          <year>2014</year>
          <volume>48</volume>
          <fpage>264</fpage>
          <lpage>266</lpage>
          <pub-id pub-id-type="pmid">24504079</pub-id>
        </element-citation>
      </ref>
      <ref id="B87">
        <label>87</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Turner</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Moorghen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Probert</surname>
              <given-names>CS</given-names>
            </name>
          </person-group>
          <article-title>Refractory coeliac disease: remission with infliximab and immunomodulators</article-title>
          <source>Eur J Gastroenterol Hepatol</source>
          <year>2005</year>
          <volume>17</volume>
          <fpage>667</fpage>
          <lpage>669</lpage>
          <pub-id pub-id-type="pmid">15879730</pub-id>
        </element-citation>
      </ref>
      <ref id="B88">
        <label>88</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gillett</surname>
              <given-names>HR</given-names>
            </name>
            <name>
              <surname>Arnott</surname>
              <given-names>ID</given-names>
            </name>
            <name>
              <surname>McIntyre</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Successful infliximab treatment for steroid-refractory celiac disease: a case report</article-title>
          <source>Gastroenterology</source>
          <year>2002</year>
          <volume>122</volume>
          <fpage>800</fpage>
          <lpage>805</lpage>
          <pub-id pub-id-type="pmid">11875014</pub-id>
        </element-citation>
      </ref>
      <ref id="B89">
        <label>89</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Costantino</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>della Torre</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lo Presti</surname>
              <given-names>MA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Treatment of life-threatening type I refractory coeliac disease with long-term infliximab</article-title>
          <source>Dig Liver Dis</source>
          <year>2008</year>
          <volume>40</volume>
          <fpage>74</fpage>
          <lpage>77</lpage>
          <pub-id pub-id-type="pmid">17382609</pub-id>
        </element-citation>
      </ref>
      <ref id="B90">
        <label>90</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chaudhary</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ghosh</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Infliximab in refractory coeliac disease</article-title>
          <source>Eur J Gastroenterol Hepatol</source>
          <year>2005</year>
          <volume>17</volume>
          <fpage>603</fpage>
          <lpage>604</lpage>
          <pub-id pub-id-type="pmid">15879720</pub-id>
        </element-citation>
      </ref>
      <ref id="B91">
        <label>91</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Booth</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Keizer</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Kamphuis</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Clark-Lewis</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Sykes</surname>
              <given-names>BD</given-names>
            </name>
          </person-group>
          <article-title>The CXCR3 binding chemokine IP-10/CXCL10: structure and receptor interactions</article-title>
          <source>Biochemistry</source>
          <year>2002</year>
          <volume>41</volume>
          <fpage>10418</fpage>
          <lpage>10425</lpage>
          <pub-id pub-id-type="pmid">12173928</pub-id>
        </element-citation>
      </ref>
      <ref id="B92">
        <label>92</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lammers</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Khandelwal</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Chaudhry</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Identification of a novel immunomodulatory gliadin peptide that causes interleukin-8 release in a chemokine receptor CXCR3-dependent manner only in patients with coeliac disease</article-title>
          <source>Immunology</source>
          <year>2011</year>
          <volume>132</volume>
          <fpage>432</fpage>
          <lpage>440</lpage>
          <pub-id pub-id-type="pmid">21091908</pub-id>
        </element-citation>
      </ref>
      <ref id="B93">
        <label>93</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Daveson</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Gaze</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Effect of hookworm infection on wheat challenge in celiac disease-a randomised double-blinded placebo controlled trial</article-title>
          <source>PloS One</source>
          <year>2011</year>
          <volume>6</volume>
          <fpage>e17366</fpage>
          <pub-id pub-id-type="pmid">21408161</pub-id>
        </element-citation>
      </ref>
      <ref id="B94">
        <label>94</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brown</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Daveson</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Marjason</surname>
              <given-names>JK</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A phase 1 study to determine safety, tolerability and bioactivity of Nexvax2 in HLA DQ2+ volunteers with celiac disease following a long-term, strict gluten-free diet</article-title>
          <source>Gastroenterology</source>
          <year>2011</year>
          <volume>140</volume>
          <fpage>S437</fpage>
          <lpage>S438</lpage>
        </element-citation>
      </ref>
      <ref id="B95">
        <label>95</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kaukinen</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Lindfors</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Maki</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Advances in the treatment of coeliac disease: an immunopathogenic perspective</article-title>
          <source>Nat Rev Gastroenterol Hepatol</source>
          <year>2014</year>
          <volume>11</volume>
          <fpage>36</fpage>
          <lpage>44</lpage>
          <pub-id pub-id-type="pmid">23917697</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="F1" orientation="portrait" position="float">
      <label>Fig. 1</label>
      <caption>
        <p>The pathogenesis of CD is multi-faceted, involving environmental (gluten, intestinal infections), genetic, and immunological factors.</p>
      </caption>
      <graphic xlink:href="vim-0030-0156-g01"/>
    </fig>
    <fig id="F2" orientation="portrait" position="float">
      <label>Fig. 2</label>
      <caption>
        <p>Novel therapeutic approaches. <bold>a</bold> Therapeutic approaches acting in the lumen of the small intestine, either binding or degrading ingested gluten peptides in the intestine (glutenases, gluten binders, neutralising antibodies). <bold>b</bold> Suggested treatment options that prevent gluten-induced effects in the intestinal epithelium: Blocking the ZOT receptor with the octapeptide AT-1001 to decrease intestinal permeability is another option. Furthermore, since deamidation of gluten peptides by tTG2 and subsequent presentation by HLA-DQ2/8 initiates the adaptive immune responses, tTG2 inhibitors and DQ2-blocking peptides seem an attractive possibility to prevent inflammation. <bold>c</bold> Therapeutic options based on prevention of immunological cascades in cells of the lamina propria (especially in patients with RCD), either by lymphocyte blocking (anti-IL-15, anti-CCR9, anti-&#x3B1;4, -&#x3B2;7) or by tolerance induction (reprinted by permission from Macmillan Publishers Ltd from [<xref rid="B95" ref-type="bibr">95</xref>]).</p>
      </caption>
      <graphic xlink:href="vim-0030-0156-g02"/>
    </fig>
    <fig id="F3" orientation="portrait" position="float">
      <label>Fig. 3</label>
      <caption>
        <p>Posttranslational modification of gluten peptides. <bold>a, b</bold> Gluten peptides that are highly resistant to intestinal proteases reach the lamina propria, either via epithelial transcytosis or due to increased epithelial tight junctional permeability. Here, they are deamidated through the activity of tissue tTG2(transglutaminase 2)-generating peptides with negatively charged amino acid residues that bind with higher affinity to the disease-associated HLA-DQ2 or HLA-DQ8 molecules. P4, P6, and P7 pockets in HLA-DQ2 and P1 and P9 pockets in HLA-DQ8 have a preference for negatively charged anchor residues (modified from [<xref rid="B3" ref-type="bibr">3</xref>]).</p>
      </caption>
      <graphic xlink:href="vim-0030-0156-g03"/>
    </fig>
    <table-wrap id="T1" orientation="portrait" position="float">
      <label>Table 1</label>
      <caption>
        <p>Treatments for CD beyond the GFD (status May 2014)</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="left" rowspan="1" colspan="1">Underlying pathology</th>
            <th align="left" rowspan="1" colspan="1">Therapeutic approach</th>
            <th align="left" rowspan="1" colspan="1">Compound/organism</th>
            <th align="left" rowspan="1" colspan="1">References</th>
          </tr>
        </thead>
        <tbody>
          <tr valign="top">
            <td align="left" rowspan="1" colspan="1">Immunodominant gluten peptides</td>
            <td align="left" rowspan="1" colspan="1">wheat variants;</td>
            <td rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1">preclinical</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1">less immunogenic ancient wheat species;</td>
            <td rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1">preclinical</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1">genetically modified (gluten-depleted)</td>
            <td rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1">preclinical</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1">wheat strains with maintained baking properties;</td>
            <td rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1">phase II clinical trial</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1">gluten detoxification;</td>
            <td align="left" rowspan="1" colspan="1">prolyl endopeptidases AN-PEP;</td>
            <td align="left" rowspan="1" colspan="1">phase II clinical trial</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1">enzymatic cleavage of gluten fragments;</td>
            <td align="left" rowspan="1" colspan="1">oral enzyme supplementation; AVL003P</td>
            <td align="left" rowspan="1" colspan="1">phase I</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1">inactivation by polymeric binders</td>
            <td align="left" rowspan="1" colspan="1">(HEMA-co-SS)</td>
            <td rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td align="left" colspan="4" rowspan="1">
              <hr/>
            </td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Impaired mucosal barrier</td>
            <td align="left" rowspan="1" colspan="1">permeability inhibition;</td>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1">zonulin/ZOT receptor blockade</td>
            <td align="left" rowspan="1" colspan="1">AT-1001 (larazotide)</td>
            <td align="left" rowspan="1" colspan="1">phase IIb clinical trial</td>
          </tr>
          <tr>
            <td align="left" colspan="4" rowspan="1">
              <hr/>
            </td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Adaptive immunity</td>
            <td align="left" rowspan="1" colspan="1">antigen presentation suppression;</td>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1">inhibitors of transglutaminase;</td>
            <td align="left" rowspan="1" colspan="1">ZED1227, Zedira</td>
            <td align="left" rowspan="1" colspan="1">phase I</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1">blockers of HLA-DQ</td>
            <td rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1">preclinical</td>
          </tr>
          <tr>
            <td align="left" colspan="4" rowspan="1">
              <hr/>
            </td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Inflammatory response</td>
            <td align="left" rowspan="1" colspan="1">anti-TNF-&#x3B1;</td>
            <td align="left" rowspan="1" colspan="1">infliximab</td>
            <td align="left" rowspan="1" colspan="1">preclinical</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1">anti-IL-15</td>
            <td align="left" rowspan="1" colspan="1">AMG 714</td>
            <td align="left" rowspan="1" colspan="1">preclinical</td>
          </tr>
          <tr>
            <td align="left" colspan="4" rowspan="1">
              <hr/>
            </td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Lymphocyte recruitment (&#x2018;homing&#x2019;)</td>
            <td align="left" rowspan="1" colspan="1">adhesion blockade;</td>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1">anti-&#x3B1;4&#x3B2;7/MAdCAM-1;</td>
            <td align="left" rowspan="1" colspan="1">natalizumab</td>
            <td align="left" rowspan="1" colspan="1">preclinical</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1">anti-CCR9/CCL25</td>
            <td align="left" rowspan="1" colspan="1">Ccx282-B, CCX025</td>
            <td align="left" rowspan="1" colspan="1">phase II concluded</td>
          </tr>
          <tr>
            <td align="left" colspan="4" rowspan="1">
              <hr/>
            </td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Immunomodulation</td>
            <td align="left" rowspan="1" colspan="1">gluten vaccination;</td>
            <td align="left" rowspan="1" colspan="1">nexvax2 trial</td>
            <td align="left" rowspan="1" colspan="1">phase IIa clinical trial</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1">parasite infection</td>
            <td align="left" rowspan="1" colspan="1"><italic>Nectarus americanus</italic> (hookworm)</td>
            <td align="left" rowspan="1" colspan="1">phase II clinical trial</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
  </floats-group>
</article>
